These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 12756135)

  • 1. Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study.
    Thobois S; Ribeiro MJ; Lohmann E; Dürr A; Pollak P; Rascol O; Guillouet S; Chapoy E; Costes N; Agid Y; Remy P; Brice A; Broussolle E;
    Arch Neurol; 2003 May; 60(5):713-8. PubMed ID: 12756135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multitracer dopaminergic PET study of young-onset parkinsonian patients with and without parkin gene mutations.
    Ribeiro MJ; Thobois S; Lohmann E; du Montcel ST; Lesage S; Pelissolo A; Dubois B; Mallet L; Pollak P; Agid Y; Broussolle E; Brice A; Remy P;
    J Nucl Med; 2009 Aug; 50(8):1244-50. PubMed ID: 19617340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism.
    Scherfler C; Khan NL; Pavese N; Eunson L; Graham E; Lees AJ; Quinn NP; Wood NW; Brooks DJ; Piccini PP
    Brain; 2004 Jun; 127(Pt 6):1332-42. PubMed ID: 15090472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans.
    Hilker R; Klein C; Hedrich K; Ozelius LJ; Vieregge P; Herholz K; Pramstaller PP; Heiss WD
    Neurosci Lett; 2002 Apr; 323(1):50-4. PubMed ID: 11911988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study.
    Khan NL; Brooks DJ; Pavese N; Sweeney MG; Wood NW; Lees AJ; Piccini P
    Brain; 2002 Oct; 125(Pt 10):2248-56. PubMed ID: 12244082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.
    Sawle GV; Playford ED; Burn DJ; Cunningham VJ; Brooks DJ
    Arch Neurol; 1994 Mar; 51(3):237-43. PubMed ID: 8129633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene.
    Hilker R; Klein C; Ghaemi M; Kis B; Strotmann T; Ozelius LJ; Lenz O; Vieregge P; Herholz K; Heiss WD; Pramstaller PP
    Ann Neurol; 2001 Mar; 49(3):367-76. PubMed ID: 11261512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity.
    Hilker R; Schweitzer K; Coburger S; Ghaemi M; Weisenbach S; Jacobs AH; Rudolf J; Herholz K; Heiss WD
    Arch Neurol; 2005 Mar; 62(3):378-82. PubMed ID: 15767502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
    Pirker W
    Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study.
    Pavese N; Khan NL; Scherfler C; Cohen L; Brooks DJ; Wood NW; Bhatia KP; Quinn NP; Lees AJ; Piccini P
    Mov Disord; 2009 Nov; 24(15):2260-6. PubMed ID: 19845000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and Parkin-linked Parkinson's disease.
    Hu MT; Scherfler C; Khan NL; Hajnal JV; Lees AJ; Quinn N; Wood NW; Brooks DJ
    Mov Disord; 2006 Mar; 21(3):299-305. PubMed ID: 16211589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism.
    Pal PK; Leung J; Hedrich K; Samii A; Lieberman A; Nausieda PA; Calne DB; Breakefield XO; Klein C; Stoessl AJ
    Mov Disord; 2002 Jul; 17(4):789-94. PubMed ID: 12210877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging of dopaminergic dysfunction with [123I]FP-CIT SPECT in early-onset parkin disease.
    Varrone A; Pellecchia MT; Amboni M; Sansone V; Salvatore E; Ghezzi D; Garavaglia B; Brice A; Brunetti A; Bonavita V; De Michele G; Salvatore M; Pappatà S; Barone P
    Neurology; 2004 Dec; 63(11):2097-103. PubMed ID: 15596756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study.
    Rinne JO; Portin R; Ruottinen H; Nurmi E; Bergman J; Haaparanta M; Solin O
    Arch Neurol; 2000 Apr; 57(4):470-5. PubMed ID: 10768619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
    Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO
    Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Presynaptic nigrostriatal function in Parkinson disease and Parkinson-plus syndromes. Comparative studies using positron emission tomography with L-6-(18F)fluorodopa].
    Cordes M; Poewe W
    Nervenarzt; 1994 Oct; 65(10):696-9. PubMed ID: 7808568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia.
    Binkofski F; Reetz K; Gaser C; Hilker R; Hagenah J; Hedrich K; van Eimeren T; Thiel A; Büchel C; Pramstaller PP; Siebner HR; Klein C
    Neurology; 2007 Aug; 69(9):842-50. PubMed ID: 17724286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS
    Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
    Rinne JO; Ruottinen H; Bergman J; Haaparanta M; Sonninen P; Solin O
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):737-41. PubMed ID: 10567489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls.
    Jokinen P; Helenius H; Rauhala E; Brück A; Eskola O; Rinne JO
    J Nucl Med; 2009 Jun; 50(6):893-9. PubMed ID: 19443601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.